| Williamston Family Dental, Llc | |
|
312 Williams St Williamston SC 29697-1900 | |
| (864) 847-4545 | |
| (864) 847-5307 |
| Full Name | Williamston Family Dental, Llc |
|---|---|
| Speciality | Dentist |
| Location | 312 Williams St, Williamston, South Carolina |
| Authorized Official Name and Position | Jody Debany (OFFICE MANAGER) |
| Authorized Official Contact | 8648474545 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Williamston Family Dental, Llc 312 Williams St Williamston SC 29697-1900 Ph: (864) 847-4545 | Williamston Family Dental, Llc 312 Williams St Williamston SC 29697-1900 Ph: (864) 847-4545 |
| NPI Number | 1003253758 |
|---|---|
| Provider Enumeration Date | 06/03/2013 |
| Last Update Date | 06/03/2013 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003253758 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 122300000X | Dentist | (* (Not Available)) | Primary |
News Archive
Earlier this week, the Congressional Budget Office advised members of Congress that the U.S. House of Representative's tax reform bill (the "Tax Cuts and Jobs Act," or H.R. 1) would result in automatic cuts to key federal programs, including a $25 billion cut to the Medicare program in 2018 as a result of existing Congressional "pay-go" rules.
Pittsburgh's Ohio Valley General Hospital, in an effort to improve patient safety, has implemented an automated system that uses barcoding and "smart" infusion system technology to ensure that patients receive the right intravenous (IV) medication at the appropriate dose and rate.
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
The U.S. Food and Drug Administration today approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
Researchers at the University of Miami School of Medicine compared the outcomes of cirrhotic patients who underwent liver transplants for nonalcoholic steatohepatitis (NASH) versus alcoholic liver disease (ETOH) and found no statistically significant differences in post-transplant survival rates between the NASH and ETOH groups
› Verified 4 days ago
Edward E. Lancater, Iii Dmd And Associates Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 312 Williams St, Williamston, SC 29697 Phone: 864-847-4545 | |
Dwh Dental Pa Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 312 Williams St, Williamston, SC 29697 Phone: 864-847-4545 |